Press Releases and Media Coverage
June 3, 2025
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
April 14, 2025
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
February 18, 2025
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
November 7, 2024
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
May 13, 2024
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
April 26, 2022
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer